> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# J&J Net Earnings Fall 95.9% To $210 Million On Talc Plan, Deal Costs, Yet Raises 2026 Outlook
- URL: https://www.bullished.co/j-and-j-net-earnings-fall-95-9-to-210-million-on-talc-plan-deal-costs-yet-raises-2026-52a07733/
- Published: 2026-10-13T12:21:09.000Z
- Updated: 2026-10-28T22:21:10.000Z
- Description: Third-quarter sales rose 5.9% to $25.4 billion, and the company lifted its full-year adjusted earnings-per-share forecast by $0.06.
- Author: Matteo Parrino
- Tags: Earnings, JNJ, Industry: Healthcare

[Johnson & Johnson](https://www.bullished.co/tag/jnj/)'s third-quarter net earnings fell 95.9% to [$210 million](https://www.sec.gov/Archives/edgar/data/0000200406/000020040626000189/a2026q3exhibit991.htm?ref=bullished.co), or $0.09 per share, from $5,152 million a year earlier, according to the earnings release filed with an [8-K](https://www.sec.gov/Archives/edgar/data/0000200406/000020040626000189/jnj-20261013.htm?ref=bullished.co) on Tuesday. The company still raised its 2026 guidance, with adjusted earnings per share now $11.10 at the midpoint.

## What the results show

The company said the per-share figure reflects a one-time special charge for the proposed talc litigation resolution, the acquisition of Firefly Bio and the collaboration with Sail Biomedicines. The earnings schedule lists $5,519 million of pre-tax litigation-related adjustments in the quarter, against $15 million a year earlier.

Adjusted earnings per share, which exclude intangible amortization and special items, were [$2.59](https://www.rte.ie/news/business/2026/1013/1595201-johnson-johnson-quarterly-results/?ref=bullished.co) versus $2.80 a year earlier, down 7.5%. Reported sales grew 5.9% to $25.4 billion ($25,399 million versus $23,993 million).

Innovative Medicine sales [rose 7.7%](https://www.rte.ie/news/business/2026/1013/1595201-johnson-johnson-quarterly-results/?ref=bullished.co) to $16,757 million, and MedTech rose 2.5% to $8,642 million. U.S. sales rose 9.1%, while international sales rose 1.5%.

Stelara, which faces generic competition, fell 54.4% to $716 million. Tremfya rose 68.3% to $2,396 million. Darzalex sales were $4,239 million, up 15.4%. RTE reported that Darzalex fell short of analyst expectations of $4.4 billion, and that Middle East conflict hurt regional sales. According to RTE, CFO Joe Wolk said Gulf states are redirecting budgets from premium healthcare toward defence.

## The raised guidance

J&J now expects estimated reported sales of $101.0 billion to $101.4 billion, a $101.2 billion midpoint, versus a $101.1 billion midpoint set on July 29\. Adjusted EPS guidance is $11.05 to $11.15, with an $11.10 midpoint, up $0.06 from $11.04.

CEO Joaquin Duato said the results give the company a "clearer line of sight to double-digit growth by the end of the decade." The release says other modeling considerations will come on the webcast.

For holders, the gap between the two profit measures is the point: reported earnings carry the talc charge and deal costs, while the adjusted figure strips most of them out.

## What to watch

J&J holds its investor call at 8:30 a.m. ET on Tuesday. JNJ shares were about 2% lower at $258.40 in Tuesday pre-market trading, versus Monday's $263.73 close, on light volume.

The call is where management is due to add its remaining modeling considerations for the rest of 2026.

Learn

- [Item 2.02: results of operations →](https://www.bullished.co/learn/8-k-items-explained/#item-202-results-of-operations)  
From 8-K Items Explained: What Every Item Code From 1.01 To 9.01 Tells You, With Examples

### Sources

- [8-K Filing — JOHNSON & JOHNSON (JNJ)](https://www.sec.gov/Archives/edgar/data/0000200406/000020040626000189/jnj-20261013.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit a2026q3exhibit991.htm — JOHNSON & JOHNSON 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0000200406/000020040626000189/a2026q3exhibit991.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit a2026q3exhibit992.htm — JOHNSON & JOHNSON 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0000200406/000020040626000189/a2026q3exhibit992.htm?ref=bullished.co) — SEC EDGAR
- [J&J beats earnings estimates; Middle East war hits sales](https://www.rte.ie/news/business/2026/1013/1595201-johnson-johnson-quarterly-results/?ref=bullished.co) — rte.ie
- [Johnson & Johnson: Q3 Earnings Snapshot](https://finance.yahoo.com/markets/stocks/articles/johnson-johnson-q3-earnings-snapshot-103723461.html?ref=bullished.co) — Associated Press

### More on Johnson & Johnson

- [J&J's Talc Reserve Is Now About $9.0 Billion, And The Ovarian Deal Hinges On 95% Of Claims](https://www.bullished.co/j-and-js-talc-reserve-is-now-about-9-0-billion-and-the-ovarian-deal-hinges-on-95-of-claims-28570823/)
- [J&J's CFO Says Company Is 'Leaning Towards A Spin' Of DePuy Synthes, Targets Mid-2027](https://www.bullished.co/j-and-js-cfo-says-company-is-leaning-towards-a-spin-of-depuy-synthes-targets-mid-2027-7cc0f26f/)

[All Johnson & Johnson (JNJ) coverage →](https://www.bullished.co/tag/jnj/)